What is AIM stock price today?

AIM (Aim Immunotech Inc) stock is trading at $0.69 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is AIM stock going up or down today?

AIM stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy AIM stock now?

The decision to buy AIM depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is AIM a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for AIM based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is AIM stock overvalued or undervalued?

Use our DCF valuation calculator to determine if AIM is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is AIM's P/E ratio?

P/E ratio data for AIM will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is AIM's market cap?

AIM (Aim Immunotech Inc) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is AIM's price to book ratio?

AIM trades at a price-to-book (P/B) ratio of 2.72, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does AIM pay dividends?

AIM does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is AIM's dividend yield?

AIM does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is AIM stock a good long-term investment?

AIM's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is AIM's revenue growth rate?

AIM has shown revenue growth of -0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for AIM are available on our dashboard with complete income statement analysis.

What are the risks of investing in AIM?

Key risks for AIM include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does AIM compare to its competitors?

Compare AIM to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize AIM's performance and positioning.

What is AIM's stock price target for 2026?

Our AI model provides price targets for AIM based on fundamental analysis: Bull case $0.90 (+30%), Base case $0.79 (+15%), Bear case $0.62 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about AIM?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for AIM. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is AIM's next earnings report?

AIM reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

AIM - Aim Immunotech Inc

NYSE * Health Care * Biotechnology

$0.69

$-0.01 (-1.31%)

About Aim Immunotech Inc

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM Key Statistics

Market Cap

$2.79M

P/B Ratio

2.72

EPS

$-18.16

Revenue Growth

-0.3%

Employees

How AIM Compares to Peers

AIM is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
AIM(This stock)	$2.79M	N/A	-0%	0.0%	-
AMGNAmgen Inc	$203.23B	26.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$183.52B	21.8	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$120.46B	31.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$81.05B	18.5	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.88B	21.6	-0%	0.1%	vs BIIB

Aim Immunotech Inc Company Information

Headquarters: Florida; U.S.A
Website: aimimmuno.com
Sector: Health Care
Industry: Biotechnology

About Aim Immunotech Inc

AIM Key Statistics

How AIM Compares to Peers

Aim Immunotech Inc Company Information

Upcoming Events for AIM